ORIC Pharmaceuticals (ORIC) pipeline and stated timing

Name in SEC filings: Oric Pharmaceuticals, Inc.

Pipeline at a glance

Program	Event	Stage	Stated timing	Filing
enozertinib / ORIC-114	/data readout	Stage not stated	second half of 2026	10-Q · Aug 3, 2026

Source: ORION, orionbiotechai.com/company/ORIC, data as of Oct 18, 2026
https://www.orionbiotechai.com/company/ORIC

Nearest upcoming stated timing: enozertinib / ORIC-114 · Topline/data readout · second half of 2026

SEC sources last checked Oct 18, 2026.

Programs and stated timing

○ Quote matched to filing (not yet reviewed by founder) · ✓ Checked by founder.

enozertinib / ORIC-114

Matched

Topline/data readoutsecond half of 2026

Stage: Not stated

Public float: $862,400,000 · as of Jun 30, 2025 · SEC filing

We expect to report data in the second half of 2026 in 1L NSCLC patients with EGFR exon 20 insertion mutations as a monotherapy and in combination with SC amivantamab, as well as in 1L NSCLC patients with EGFR atypical mutations as a monotherapy.

10-Q · Filed Aug 3, 2026 · Last checked Oct 18, 2026

Source details

Accession 0001193125-26-330631

Alert me · Calendar: same stage and window-end month (2026-12)

How this date was described over time

Company periods and sentences are quoted as written. A matching disclosure uses the SEC filing date for the same program and event type. As of Oct 19, 2026.

Program / event

Stated period and SEC wording

Disclosure in stated period

enozertinib / ORIC-114Clinical results

second half of 2026

“We expect to report data in the second half of 2026 in 1L NSCLC patients with EGFR exon 20 insertion mutations as a monotherapy and in combination with SC amivantamab, as well as in 1L NSCLC patients with EGFR atypical mutations as a monotherapy.”

Filed Aug 3, 2026 · 10-Q

Still within period

As of Oct 19, 2026

enozertinib / ORIC-114Clinical results

second half of 2026

“We expect to report data in the second half of 2026 in 1L NSCLC patients with EGFR exon 20 insertion mutations as a monotherapy and in combination with SC amivantamab, as well as in 1L NSCLC patients with EGFR PACC mutations as a monotherapy.”

Filed May 4, 2026 · 10-Q

Still within period

As of Oct 19, 2026

“Not compared” means ORION has not matched this wording against a complete set of SEC filings for its period. It says nothing either way about whether a matching filing exists. Wording without exact dates is not given calendar dates.

Watch ORIC

Or email ORION to ask for this Watch.

Request another SEC timing statement

Suggest an SEC timing statement to add for ORIC. You can include the original filing link in your note. The founder reads each request by hand.

Or email ORION.

Reading these records

First stated window: The timing wording in the earliest company statement located within the sources checked, quoted as written (for example “2H 2026”). An earlier statement may exist outside those sources.
Disclosure date: The date of the filing or company release that disclosed the readout. “None found” means no such disclosure was located in the sources checked. SEC filings were searched through the “SEC filings searched through” date shown.
1H, 2H, 1Q–4Q: First or second half, or first to fourth quarter, of the year named, as the company wrote it. Equivalent notations are compared together; the original wording stays visible.
SEC original: The filing as published on the SEC EDGAR system. “Company original” is the release on the company's own investor site.
Status: One of seven labels set by founder review of the original filings. Definitions: Methodology.

See ORIC in the calendar · Review labels and methodology